NEW YORK (360Dx) – Nonprofit organization PATH said on Wednesday it is partnering with SD Biosensor to further develop a diagnostic test in support of efforts to eliminate malaria.

The two entities have developed the Standard G6PD test to guide clinical care of patients with Plasmodium vivax malaria who also have a hereditary enzyme deficiency that can result in severe anemia if they are treated with 8-aminoquinoline-based drugs for the infection. The deficiency is known as glucose-6-phosphate-dehydrogenase (G6PD) deficiency.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease. 

Sponsored by

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.